Cargando…

SAT-158 New Data on High Prevalence and Time of Occurrence of New Onset Hypothyroidism Associated with Mitotane Therapy in a Cohort of Adrenocortical Cancer

Context. Mitotane is a steroidogenesis inhibitor and an adrenocorticolytic drug used to treat adrenocortical cancer (ACC). Central hypothyroidism is recognized in mitotane-treated patients and recent data suggested that mitotane could have an inhibitory effect on TSH-secreting cells in the pituitary...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poirier, Jonathan, Lacroix, André, Olney, Harold J, Bourdeau, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Adrenal
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7207913/ http://dx.doi.org/10.1210/jendso/bvaa046.1590

Ejemplares similares

SAT-169 Adrenocortical Cancer Is Diagnosed at Large Size and Advanced Stage in a Canadian Referral Center; Focus on Modes of Presentation Depending on Stages
por: Poirier, Jonathan, et al.
Publicado: (2020)

RF21 | PSUN07 Germline Genetic Testing in a Cohort of Adults with Adrenocortical Carcinoma : Insights From a Clinical Care Setting
por: Mourot, Aurélie, et al.
Publicado: (2022)

THU609 Timeline For Undetectable Mitotane Plasma Levels In Adrenocortical Carcinoma Patients After Stopping Treatment
por: Younes, Nada, et al.
Publicado: (2023)

Results of the ADIUVO Study, the First Randomized Trial on Adjuvant Mitotane in Adrenocortical Carcinoma Patients
por: Terzolo, Massimo, et al.
Publicado: (2021)

Characterization of hyperlipidemia secondary to mitotane in adrenocortical carcinoma
por: Gagnon, Nadia, et al.
Publicado: (2022)

SAT-LB064 Mitotane Induces Autophagy: A Mechanism to Promote Chemoresistance in Adrenocortical Carcinoma
por: Tompkins, Kenneth, et al.
Publicado: (2019)

Investigating the Role of Cholesterol and Lipid Trafficking in Mitotane Resistance in Adrenocortical Carcinoma
por: Warde, Kate, et al.
Publicado: (2021)

SUN-216 Investigating the Role of the Liver X Receptor in Potentiating Mitotane Therapy in Adrenocortical Carcinoma
por: Warde, Kate, et al.
Publicado: (2020)

ODP597 Clinical case of uncomplicated pregnancy in a patient with adrenocortical carcinoma during treatment with mitotane
por: Beltsevich, Dmitry, et al.
Publicado: (2022)

Recovery of Adrenal Insufficiency Is Frequent After Adjuvant Mitotane Therapy in Patients with Adrenocortical Carcinoma
por: Poirier, Jonathan, et al.
Publicado: (2020)

Efficacy of Treatment With PARP Inhibitor and Immunotherapy for Aggressive Adrenocortical Carcinomawith Cushing’s Syndrome Refractory to Treatment With EDP Chemotherapy and Mitotane
por: Greb, Alexandra C, et al.
Publicado: (2021)

SAT313 Therapeutic Dosing Of Steroids In Patients On Mitotane
por: Pham, Christopher, et al.
Publicado: (2023)

SUN-350 Sterol-O-Acyl Transferase 1 Protein Expression Alone Is Not Sufficient to Predict Response to Mitotane Treatment in Adrenocortical Carcinoma
por: Weigand, Isabel, et al.
Publicado: (2019)

ODP049 Oncocytic adrenocortical carcinoma misdiagnosed as renal oncocytoma and use of urinary steroid profiling in disease monitoring after mitotane therapy
por: Wong, Cheuk Lik, et al.
Publicado: (2022)

Rapid and Complete Remission of Metastatic Adrenocortical Carcinoma Persisting 10 Years After Treatment With Mitotane Monotherapy: Case Report and Review of the Literature
por: Ghorayeb, Nada El, et al.
Publicado: (2016)

SAT-207 Adrenocortical Carcinoma in Untreated Congenital Adrenal Hyperplasia
por: David, Julia, et al.
Publicado: (2020)

SUN-373 Small Adrenal Incidentaloma Stable in Size Becoming a Stage IV Adrenocortical Carcinoma 10 Years Later in a Young Patient Carrying a Germline APC Variant of Uncertain Significance (VUS)
por: Boily, Pascale, et al.
Publicado: (2019)

MON-209 Identification of a New Heterozygous Germline ARMC5 Deletion in a Familial Case of Primary Bilateral Macronodular Adrenal Hyperplasia Co-Secreting Cortisol and Aldosterone
por: Salle, Stefanie Parisien-La, et al.
Publicado: (2020)

SAT-350 Comparative Proteomic Analysis of Various Forms of Bilateral Adrenocortical Hyperplasia
por: Berthon, Annabel, et al.
Publicado: (2019)

SAT-172 FDG PET/CT in Benign vs. Malignant Adrenocortical Tumors
por: He, Xin, et al.
Publicado: (2020)

SAT-180 Adrenocortical Carcinoma - A Tertiary Center’s Recent 5-Year Experience
por: Ehrenwald, Michal, et al.
Publicado: (2020)

SAT-226 Lifestyle Modifications or Adrenalectomy? Pheochromocytoma Presenting with New Onset Diabetes Mellitus
por: Sosa-Pagan, Max, et al.
Publicado: (2020)

SAT-354 Characterization of Cell Death Induced by SOAT1 Inhibition in Adrenocortical Carcinoma Cells
por: Weigand, Isabel, et al.
Publicado: (2019)

SAT-165 Sterol O-Acyl Transferase 1 as a Prognostic Marker of Adrenocortical Carcinoma
por: Lacombe, Amanda Meneses Ferreira, et al.
Publicado: (2020)

FRI199 Severe Hypertriglyceridemia And Acute Pancreatitis In A Patient With Adrenocortical Carcinoma (ACC) Taking Mitotane
por: Cortez, Briana Noel, et al.
Publicado: (2023)

SAT-179 Increased Telomere Length in Adrenocortical Tumors Is Associated with Abnormal Expression of Chromatin Remodelling Factors
por: Stecchini, Monica F, et al.
Publicado: (2020)

SAT-178 Incidence, Patterns of Clinical Presentation, and Outcomes of Patients with Brain Metastasis Due to Adrenocortical Carcinoma
por: Amorim, Larissa Costa, et al.
Publicado: (2020)

SAT-173 SAMD9 (Sterile Alpha Motif Domain-Containing 9) Expression in Adrenocortical Tumors
por: Bueno, Ana C, et al.
Publicado: (2020)

PSAT096 Development and Validation of Mitotane Determination in Plasma Samples by LC-DAD
por: Lima-Valassi, Helena P, et al.
Publicado: (2022)

SAT-351 CYP11B1 Is a Highly Accurate Marker of Malignancy in Functioning Adrenocortical Tumors
por: Pereira, Sofia, et al.
Publicado: (2019)

SAT-171 Adrenocortical Carcinoma in Thailand: A 10-Year Retrospective Review in a Single Tertiary Center
por: Gomutput, Patrawon, et al.
Publicado: (2020)

Mitotane in adrenocortical carcinoma.
por: Vassilopoulou-Sellin, R., et al.
Publicado: (1994)

SAT-359 Involvement of Inflammation and Oxidative Stress in the Adrenocortical Dysfunction Displayed by Insulin Resitant Rats: Effect of Hemin Treatment
por: Vecino, Carolina, et al.
Publicado: (2019)

SAT-LB44 WNT2B Regulates Adrenocortical Progenitor Cell Fate And Zona Glomerulosa Identity In Vivo
por: Little, Donald W, et al.
Publicado: (2020)

SAT-LB34 Repressive Epigenetic Programs Reinforce Steroidogenic Differentiation and Wnt/β-Catenin Signaling in Aggressive Adrenocortical Carcinoma
por: Mohan, Dipika R, et al.
Publicado: (2020)

SAT-LB36 Distinct Vitamin D Receptor DNA Methylation Profiles Are Associated With the Outcome of Pediatric Patients With Adrenocortical Tumors
por: Bueno, Ana Carolina, et al.
Publicado: (2020)

SAT-353 The Synthetic Vitamin D Analog EB1089 Restricts Adrenocortical Tumor Proliferation in NCI-H295 Xenograft Model
por: Bueno, Ana, et al.
Publicado: (2019)

SAT-155 High Prevalence Alterations on DNA Mismatch Repair Genes Related to Lynch Syndrome in Pediatric Patients with Adrenocortical Tumor Carried of the Germline Mutation on TP53
por: Brondani, Vânia Balderrama, et al.
Publicado: (2020)

ODP583 Screening for Pheochromocytoma in a Cohort of Patients with Takotsubo Cardiomyopathy: New insights on Prevalence and Screening Tests Reliability Surrounding the Acute Cardiac Event
por: Bitton, Yoel, et al.
Publicado: (2022)

What Is the Optimal Duration of Adjuvant Mitotane Therapy in Adrenocortical Carcinoma? An Unanswered Question
por: Basile, Vittoria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_209r9vs0o4t3gj88bgvak1p560